Literature DB >> 32800486

Decreased survival in cystic fibrosis patients with a positive screen for depression.

Michael S Schechter1, Joshua S Ostrenga2, Aliza K Fink2, David H Barker3, Gregory S Sawicki4, Alexandra L Quittner5.   

Abstract

BACKGROUND: The International Depression Epidemiological Study (TIDES) found elevated rates of screen positivity for depression and anxiety among individuals with cystic fibrosis (CF). Depression is associated with worse adherence and health-related quality of life in CF. We investigated the relationship with mortality.
METHODS: Subjects were untransplanted participants in TIDES 12+ years of age receiving care at one of 45 collaborating US CF care centers who completed the Hospital Anxiety and Depression Scale and/or Center for Epidemiologic Studies Depression Scale during a stable visit between 2006 and 2010. Clinical characteristics and mortality data were obtained from the CF Foundation Patient Registry. The association of a positive screen with 5-year survival was evaluated using Cox Proportional Hazards modeling.
RESULTS: Of 1005 eligible patients, 25% screened positive for depression and 34% screened positive for anxiety. Patients who screened positive for depression were more likely to be older, have a residual function mutation, public insurance, and more pulmonary exacerbations in the screening year. There were 96 deaths. The unadjusted 5-year Hazard Ratio (HR) for death among those with depression was 2.0; 95% CI (1.3, 3.0)]. When adjusted for predetermined potential confounders the HR for the entire population was 1.4; 95% CI (0.9, 2.2). The adjusted HR was higher in adults [1.6; 95% CI (1.0, 2.4)] and those screening in the severe range [2.0; 95% CI (1.2, 3.4)]. Anxiety was not associated with mortality.
CONCLUSIONS: A positive depression screen is associated with increased mortality among adults with CF. Research into the etiology of this relationship is needed.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Anxiety; Cystic fibrosis; Depression; Mental health; Mortality

Mesh:

Year:  2020        PMID: 32800486     DOI: 10.1016/j.jcf.2020.07.020

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

Review 1.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

Review 2.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.

Authors:  Renée V E Dagenais; Victoria C H Su; Bradley S Quon
Journal:  J Clin Med       Date:  2020-12-23       Impact factor: 4.241

3.  Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis.

Authors:  Beth A Smith; Anna M Georgiopoulos; Amy Mueller; Janice Abbott; Paula Lomas; Enid Aliaj; Alexandra L Quittner
Journal:  J Cyst Fibros       Date:  2021-12       Impact factor: 5.482

4.  Regional brain tissue changes in patients with cystic fibrosis.

Authors:  Bhaswati Roy; Marlyn S Woo; Susana Vacas; Patricia Eshaghian; Adupa P Rao; Rajesh Kumar
Journal:  J Transl Med       Date:  2021-10-09       Impact factor: 5.531

5.  Anxiety and depression in Dutch patients with primary ciliary dyskinesia and their caregivers: associations with health-related quality of life.

Authors:  Marieke Verkleij; Iris Appelman; Josje Altenburg; Jos Twisk; Alexandra L Quittner; Eric Haarman
Journal:  ERJ Open Res       Date:  2021-10-25

6.  Living with cystic fibrosis during the COVID-19 pandemic: a social connectedness perspective.

Authors:  Maggie Harrigan; Kellie Bennett; Siobhain Mulrennan; Melanie Jessup
Journal:  Int J Qual Stud Health Well-being       Date:  2022-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.